1M Pharm Student, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, Kerala, India
2Professor, Department of Gastroenterology, Amrita Institute of Medical Sciences and Research Centre, Kochi
3Lecturer, Department of Biostatistics, School of Medicine, Amrita Vishwa Vidyapeetham, Kochi
4Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, Kerala
*Corresponding Author E-mail: roshnipr@aims.amrita.edu
Online published on 18 May, 2019.
There are no guidelines for use of diabetic medications in pancreatic diabetes. Hence we attempted to the benefits of antidiabetic agents in pancreatic diabetes.
a total of 670 chronic pancreatitis patients are selected. Out of that about 126 patients with pancreatic diabetic are selected for the study. The data collected from 2010.
In this study mean age was found to be 53.86±12.53. The male patients (73.8%) were more predominant in this study than female patients (26.2%). The complications of chronic pancreatitis among 126 patients, 126 (100) patient had diabetes mellitus (DM), 100 (79) patients had pain. Among 126 patients 52 (41.3%) patients had taken insulin only, 21 (16.7%) patients had taken insulin+ oral combination, 16 (12.7%) patients had taken Biguanides, 13 (10.3%) of patients had taken oral combinations, 13 (10.3%) patients had taken alpha glucosidase inhibitors, 11 (8.7%) patients who are taken sulfonyl ureas. Most of the patients took insulin monotherapy.
Insulin was most preferred agent. Metformin was the most commonly preferred oral antidiabetic agent.
Chronic Pancreatitis, type3c DM, pancreatic enzymes, Pseudocyst, Malabsorption
